Tucatinib is a medication that targets specific proteins (HER2) in breast cancer cells. It’s a tablet that helps block the growth and spread of cancer cells, particularly in cases where the cancer has spread to the brain.

Pertuzumab is an antibody treatment that attaches to HER2-positive breast cancer cells. It works by blocking signals that cause cancer cells to grow and divide, and it helps the immune system identify and fight cancer cells.

Trastuzumab is also an antibody treatment specifically designed for HER2-positive breast cancer. It works by attaching to the HER2 proteins on cancer cells, helping to slow down or stop their growth. It also helps the body’s immune system fight the cancer cells.

These three medications are used together to treat breast cancer that has spread to the brain, particularly in patients whose cancer cells have high levels of a protein called HER2.

HER2-Positive Metastatic Breast Cancer with Brain Metastases – A form of breast cancer that tests positive for a protein called HER2 (Human Epidermal Growth Factor Receptor 2) and has spread beyond the breast to distant parts of the body, specifically affecting the brain. In this condition, cancer cells have an excess of HER2 protein on their surface, which promotes cancer cell growth. The disease begins in the breast tissue and later spreads (metastasizes) to form secondary tumors in the brain. This particular presentation involves a situation where the cancer progression is observed primarily in the brain while other metastatic sites remain stable. The presence of brain metastases represents an advanced stage of the disease that requires specific medical attention.